Cargando…

Pharmacy Compounding Primer for Physicians: Prescriber Beware

Since the development of federal standards for drug approval, the practice of medicine has historically involved the compounding of medications based on a physician’s determination that a US FDA-approved product either did not exist, or could not be used for medical reasons. Today, prescriptions for...

Descripción completa

Detalles Bibliográficos
Autores principales: Sellers, Sarah, Utian, Wulf H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695671/
https://www.ncbi.nlm.nih.gov/pubmed/23039281
http://dx.doi.org/10.2165/11640850-000000000-00000
_version_ 1782274995741786112
author Sellers, Sarah
Utian, Wulf H.
author_facet Sellers, Sarah
Utian, Wulf H.
author_sort Sellers, Sarah
collection PubMed
description Since the development of federal standards for drug approval, the practice of medicine has historically involved the compounding of medications based on a physician’s determination that a US FDA-approved product either did not exist, or could not be used for medical reasons. Today, prescriptions for non-FDA-approved compounded drugs may be driven by fanciful and largely unregulated pharmacy advertisements to physicians and patients and/or payer reimbursement policies, thus placing prescribers in the backseat for clinical decision making. This article outlines essential differences between FDA-approved drugs and compounded drugs and reasserts the primary medical role of physicians for determining what medical circumstances may necessitate treatment with non-FDA-approved products. In addition, liability concerns when prescribing non-FDA-approved drugs are discussed. While representing a US perspective, underlying principles apply globally in the setting of magistral and extemporaneous formulations produced outside national regulatory frameworks.
format Online
Article
Text
id pubmed-3695671
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-36956712013-07-18 Pharmacy Compounding Primer for Physicians: Prescriber Beware Sellers, Sarah Utian, Wulf H. Drugs Current Opinion Since the development of federal standards for drug approval, the practice of medicine has historically involved the compounding of medications based on a physician’s determination that a US FDA-approved product either did not exist, or could not be used for medical reasons. Today, prescriptions for non-FDA-approved compounded drugs may be driven by fanciful and largely unregulated pharmacy advertisements to physicians and patients and/or payer reimbursement policies, thus placing prescribers in the backseat for clinical decision making. This article outlines essential differences between FDA-approved drugs and compounded drugs and reasserts the primary medical role of physicians for determining what medical circumstances may necessitate treatment with non-FDA-approved products. In addition, liability concerns when prescribing non-FDA-approved drugs are discussed. While representing a US perspective, underlying principles apply globally in the setting of magistral and extemporaneous formulations produced outside national regulatory frameworks. Springer International Publishing 2012-12-25 2012 /pmc/articles/PMC3695671/ /pubmed/23039281 http://dx.doi.org/10.2165/11640850-000000000-00000 Text en © Springer International Publishing AG 2012
spellingShingle Current Opinion
Sellers, Sarah
Utian, Wulf H.
Pharmacy Compounding Primer for Physicians: Prescriber Beware
title Pharmacy Compounding Primer for Physicians: Prescriber Beware
title_full Pharmacy Compounding Primer for Physicians: Prescriber Beware
title_fullStr Pharmacy Compounding Primer for Physicians: Prescriber Beware
title_full_unstemmed Pharmacy Compounding Primer for Physicians: Prescriber Beware
title_short Pharmacy Compounding Primer for Physicians: Prescriber Beware
title_sort pharmacy compounding primer for physicians: prescriber beware
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695671/
https://www.ncbi.nlm.nih.gov/pubmed/23039281
http://dx.doi.org/10.2165/11640850-000000000-00000
work_keys_str_mv AT sellerssarah pharmacycompoundingprimerforphysiciansprescriberbeware
AT utianwulfh pharmacycompoundingprimerforphysiciansprescriberbeware